Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective proteogenomics-driven targeted therapy basket trial (no.3 gamma IFN subprotocol)
KCT0010416Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of interferon gamma-1b in biliary cancer, pancreatic cancer (PC), triple-negative breast cancer (TNBC), small bowel cancer, colorectal cancer (CRC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
interferon gamma-1b
03
Conditions
biliary cancerpancreatic cancer (PC)triple-negative breast cancer (TNBC)small bowel cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on KCT0010416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010416.